Modulators of the eIF2alpha pathway
US-10343981-B2 · Jul 9, 2019 · US
Modulators of the eIF2alpha pathway
US11220477B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11220477-B2 |
| Application number | US-201916418858-A |
| Country | US |
| Kind code | B2 |
| Filing date | May 21, 2019 |
| Priority date | Mar 15, 2013 |
| Publication date | Jan 11, 2022 |
| Grant date | Jan 11, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Provided herein, inter alia, are compounds and methods useful for modulating the translational effects of eIF2α phosphorylation, the Integrated Stress Response (ISR), and the unfolded protein response (UPR); for treating diseases; for increasing protein production, and for improving long-term memory.
First claim
Opening claim text (preview).
What is claimed is: 1. A compound of formula (IIIb) or pharmaceutically acceptable salt thereof: wherein: R 5.1 and R 6.1 are independently halogen, —CF 3 , —CN, —N 3 , substituted or unsubstituted C 1 -C 4 alkyl, substituted or unsubstituted 2 to 4 membered heteroalkyl, substituted or unsubstituted 5 to 6 membered heteroaryl, and R 5.2 and R 6.2 are independently halogen, —CCSi(CH 3 ) 3 , —CF 3 , —NO 2 , —CN, —N 3 , substituted or unsubstituted C 1 -C 4 alkyl, substituted or unsubstituted 2 to 4 membered heteroalkyl, substituted or unsubstituted 5 to 6 membered heteroaryl, 2. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound, or pharmaceutically acceptable salt thereof, of claim 1 . 3. A compound selected from the following: 4. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of claim 3 .
Assignees
Inventors
Classifications
- A61K31/165Primary
having aromatic rings, e.g. colchicine, atenolol, progabide · CPC title
with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton · CPC title
having carbon atoms of amidino groups bound to acyclic carbon atoms · CPC title
the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups · CPC title
with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a ring other than a six-membered aromatic ring · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11220477B2 cover?
- Provided herein, inter alia, are compounds and methods useful for modulating the translational effects of eIF2α phosphorylation, the Integrated Stress Response (ISR), and the unfolded protein response (UPR); for treating diseases; for increasing protein production, and for improving long-term memory.
- Who is the assignee on this patent?
- Univ California
- What technology area does this patent fall under?
- Primary CPC classification A61K31/165. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).